Laboratory InsightsClinical Briefs and expert insights on evolving diagnostics

This clinical brief provides updated HBV testing guidance, including revised U.S. CDC recommendations for triple analyte screening (HBsAg, Anti-HBs, Total anti-HBc) and universal adult testing at least once. It summarizes common testing practices, associated health and economic benefits, and peer-reviewed studies comparing automated HBsAg assay performance, including detection of mutant strains.

This clinical brief provides updated HBV testing guidance, including revised U.S. CDC recommendations for triple analyte screening (HBsAg, Anti-HBs, Total anti-HBc) and universal adult testing at least once. It summarizes common testing practices, associated health and economic benefits, and peer-reviewed studies comparing automated HBsAg assay performance, including detection of mutant strains.

This clinical brief outlines updated 2030 HIV elimination targets and WHO guidance expanding testing modalities, including self-testing, to improve detection in underserved populations. It reviews the importance of antigen-antibody assays, recommended algorithms, and U.S. CDC data showing CHIV’s strong performance compared to other automated assays for early infection detection.

This clinical brief provides educational content on syphilis infection, detailing non-treponemal and treponemal testing methods and diagnostic algorithms, including traditional and reverse approaches. It also highlights the clinical and operational benefits of automated treponemal assays within reverse testing algorithms recommended by guidelines.

This clinical brief summarizes recent international and U.S. guidelines on the clinical use of PCT, emphasizing its role in reducing antibiotic duration in sCAP and guiding initiation in adults with suspected LRTI or exacerbations of asthma or COPD. It also notes that only B·R·A·H·M·S PCT-licensed assays, such as the Atellica IM B·R·A·H·M·S PCT assay, are approved for all FDA and CE-mark indications.

The clinical brief shows that shifting to a FIB‑4/ELF pathway can reduce unnecessary healthcare visits, optimize resource use, and significantly cut patient‑travel‑related CO2 emissions.

This clinical brief informs on three recent publications confirming that testing strategies using NITs for liver fibrosis are cost-effective and can reduce healthcare costs in managing MASLD in the U.S. and UK.

This clinical brief outlines the inclusion of ELF test in the Rezdiffra prescribing information and discusses noninvasive blood tests for liver fibrosis.

This clinical brief reviews European MASLD guidelines from EASL, EASD, and EASO, including references to ELF Test and VCTE in second‑line testing strategies.